22UA:FRA
BioNTech
79,10 €
arrow_downward
−0,88%(−0,70) 1D
14. okt., 17:40:57 GMT +2 · EUR
search
Vsi simboli
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za 22UA …
Odpri
79,65 €
Visoka
80,55 €
Nizka
79,10 €
Tržna kapitalizacija
22,45 mrd.
Povprečni promet
1,30 tis.
Promet
802,00
52-tedenski najvišji tečaj
105,50 €
52-tedenski najnižji tečaj
68,00 €
Št. zaposlenih
8 tis.
Odpri
79,65 €
Visoka
80,55 €
Nizka
79,10 €
Tržna kapitalizacija
22,45 mrd.
Povprečni promet
1,30 tis.
Promet
802,00
52-tedenski najvišji tečaj
105,50 €
52-tedenski najnižji tečaj
68,00 €
Št. zaposlenih
8 tis.
Novice
Iz spletnih virov in novičarskih partnerjev
Simply Wall Street
·
pred 12 urami
BioNTech Stock Faces Questions After Cancer Trial Missed Progression Free Survival Goal
TradingKey
·
pred 21 urami
Biontech SE Stock (BNTX) Closed Down by 7.13% on Oct 13: Drivers Behind the Movement
GuruFocus
·
pred 1 dnevom
BioNTech (BNTX) Shares Slide After BNT113 Vaccine Misses Progres
Profil
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Vizitka: BioNTech